Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, Ross AM, Fischer KC, Pomilio G, Morris R, Georgiou A, Litalien V, Brown FC, Roberts AW, Strasser A, Wei AH, Kelly GL. Diepstraten ST, et al. Among authors: wei ah. Cancer Cell. 2024 May 13;42(5):850-868.e9. doi: 10.1016/j.ccell.2024.04.004. Epub 2024 Apr 25. Cancer Cell. 2024. PMID: 38670091 Free article.
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. Merino D, et al. Among authors: wei ah. Cancer Cell. 2018 Dec 10;34(6):879-891. doi: 10.1016/j.ccell.2018.11.004. Cancer Cell. 2018. PMID: 30537511 Free article. Review.
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death.
Garciaz S, Guirguis AA, Müller S, Brown FC, Chan YC, Motazedian A, Rowe CL, Kuzich JA, Chan KL, Tran K, Smith L, MacPherson L, Liddicoat B, Lam EYN, Cañeque T, Burr ML, Litalien V, Pomilio G, Poplineau M, Duprez E, Dawson SJ, Ramm G, Cox AG, Brown KK, Huang DCS, Wei AH, McArthur K, Rodriguez R, Dawson MA. Garciaz S, et al. Among authors: wei ah. Cancer Discov. 2022 Mar 1;12(3):774-791. doi: 10.1158/2159-8290.CD-21-0522. Cancer Discov. 2022. PMID: 34862195 Free PMC article.
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O. Kotschy A, et al. Among authors: wei ah. Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19. Nature. 2016. PMID: 27760111
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models.
Morrish E, Copeland A, Moujalled DM, Powell JA, Silke N, Lin A, Jarman KE, Sandow JJ, Ebert G, Mackiewicz L, Beach JA, Christie EL, Lewis AC, Pomilio G, Fischer KC, MacPherson L, Bowtell DDL, Webb AI, Pellegrini M, Dawson MA, Pitson SM, Wei AH, Silke J, Brumatti G. Morrish E, et al. Among authors: wei ah. Blood Adv. 2020 Oct 27;4(20):5062-5077. doi: 10.1182/bloodadvances.2020001576. Blood Adv. 2020. PMID: 33080008 Free PMC article.
Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses.
Chan KL, Gomez J, Cardinez C, Kumari N, Sparbier CE, Lam EYN, Yeung MM, Garciaz S, Kuzich JA, Ong DM, Brown FC, Chan YC, Vassiliadis D, Wainwright EN, Motazedian A, Gillespie A, Fennell KA, Lai J, House IG, Macpherson L, Ang CS, Dawson SJ, Beavis PA, Wei AH, Burr ML, Dawson MA. Chan KL, et al. Among authors: wei ah. Cancer Cell. 2022 Oct 10;40(10):1190-1206.e9. doi: 10.1016/j.ccell.2022.09.007. Epub 2022 Sep 29. Cancer Cell. 2022. PMID: 36179686 Free PMC article.
211 results